High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia
- 29 February 1984
- journal article
- editorial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 20 (2) , 297-300
- https://doi.org/10.1016/0277-5379(84)90201-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cytosine arabinoside transport by human leukaemic cellsEuropean Journal of Cancer and Clinical Oncology, 1983
- Therapy of Secondary Acute Nonlymphocytic Leukemia with CytarabineNew England Journal of Medicine, 1983
- Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: Utility of day 6 bone marrow biopsyLeukemia Research, 1983
- Topical Corticosteroid Therapy for Corneal Toxicity from Systemically Administered CytarabineAmerican Journal of Ophthalmology, 1982
- The treatment of acute myelocytic leukemia in patients 30 years of age and youngerAmerican Journal of Hematology, 1982
- Enzymology of cytosine arabinosideMedical and Pediatric Oncology, 1982
- Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemiaMedical and Pediatric Oncology, 1982
- High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimensMedical and Pediatric Oncology, 1982
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979
- Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemiaCancer, 1975